Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Redburn Atlantic

Redburn Atlantic upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a neutral rating to a buy rating in a report published on Friday, MarketBeat.com reports. The firm currently has $13.00 price target on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, November 11th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $10.15.

Autolus Therapeutics Stock Down 2.9 %

Shares of AUTL stock opened at $2.99 on Friday. Autolus Therapeutics has a twelve month low of $2.92 and a twelve month high of $7.45. The stock’s fifty day simple moving average is $3.88 and its 200 day simple moving average is $3.98. The firm has a market capitalization of $795.62 million, a P/E ratio of -2.47 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the prior year, the business earned ($0.26) earnings per share. As a group, equities research analysts expect that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC bought a new position in Autolus Therapeutics during the 2nd quarter worth approximately $43,000. Capstone Investment Advisors LLC bought a new position in Autolus Therapeutics during the third quarter worth $51,000. Bayesian Capital Management LP acquired a new position in Autolus Therapeutics in the first quarter valued at $100,000. Daiwa Securities Group Inc. boosted its position in Autolus Therapeutics by 2,659.7% during the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after acquiring an additional 15,293 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. bought a new stake in Autolus Therapeutics during the first quarter valued at $108,000. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.